Physician profile
Charles Allred
NPI 1437310810
$9,505.82
in general payments reported to CMS, 2019-2025
38 companies · $2,729 in 2025
The $2,729 reported for 2025 was more than what 89% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.88 · 2020: $45.45 · 2022: $1,629 · 2023: $2,682 · 2024: $2,380 · 2025: $2,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,690 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,690.39 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,652.46 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,591.27 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Harmony Biosciences LLC | $711.84 | 2022-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $585.49 | 2022-2025 | Dupixent |
| Insmed, INC. | $460.65 | 2022-2024 | Arikayce |
| Mylan Specialty L.P. | $454.27 | 2022-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.09 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $374.90 | 2022-2024 | Xarelto |
| Jazz Pharmaceuticals INC. | $302.74 | 2023-2024 | |
| Axsome Therapeutics, INC. | $268.87 | 2023-2025 | Sunosi |
| Grifols USA, LLC | $259.06 | 2023-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Verona Pharma, INC. | $227.35 | 2025 | Ohtuvayre |
| Electromed, INC. | $185.30 | 2024-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $173.82 | 2023-2024 | |
| Genzyme Corporation | $165.13 | 2022-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $159.53 | 2022-2025 | Purified Cortrophin Gel |
| Philips North America LLC | $144.80 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Viatris Specialty LLC | $141.21 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $135.28 | 2024-2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $116.64 | 2022-2023 | Acthar |
| Amgen INC. | $109.97 | 2022-2024 | Tezspire |
| Novo Nordisk INC | $101.72 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $96.97 | 2023-2024 | Teflaro, Avycaz |
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 | |
| United Therapeutics Corporation | $75.44 | 2022-2024 | Tyvaso |
| Lilly USA, LLC | $74.32 | 2024-2025 | Zepbound |
| Pfizer INC. | $67.77 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $63.53 | 2023 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $60.53 | 2022-2023 | |
| Inogen, INC. | $49.09 | 2024-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Baxter Healthcare | $38.90 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Actelion Pharmaceuticals US, INC. | $32.11 | 2022 | |
| Resmed Corp | $24.08 | 2024 | |
| Tactile Systems Technology INC | $23.62 | 2024 | Flexitouch Plus, Entre Plus |
| Alexion Pharmaceuticals, INC. | $23.55 | 2024 | Ultomiris |
| Vifor Pharma, INC. | $22.85 | 2025 | Zemaira |
| Nabriva Therapeutics, Plc | $17.11 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.06 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Allred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.